MOHAMAD KASSAR, M.D.

Leuprolide acetate (for depot suspension), 7.5 mg

Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg

Administration of chemotherapy into vein, 1 hour or less

Biopsy and aspiration of bone marrow sample for diagnosis

Administration of chemotherapy into vein using push technique

New patient office or other outpatient visit, 60-74 minutes

Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes

Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg

Transitional care management services for problem of at least moderate complexity

Administration of additional new drug or substance into vein, 1 hour or less

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Established patient office or other outpatient visit, 40-54 minutes

Injection, carboplatin, 50 mg

Flow cytometry technique for dna or cell analysis, first marker

Administration of additional new drug or substance into vein using push technique

Injection, fulvestrant, 25 mg

Infusion into a vein for hydration, 31-60 minutes

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

Injection, atezolizumab, 10 mg

Established patient office or other outpatient visit, 30-39 minutes

Cyclophosphamide, 100 mg

Injection, bevacizumab, 10 mg

Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle

Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg

Flow cytometry technique for dna or cell analysis, each additional marker

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes

Administration of chemotherapy into vein, each additional hour

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Established patient office or other outpatient visit, 20-29 minutes

Injection, pembrolizumab, 1 mg

Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle

Immunologic analysis for detection of tumor antigen, quantitative; ca 125

Injection, palonosetron hcl, 25 mcg

Irrigation of implanted venous access drug delivery device

Injection of additional new drug or substance into vein

Telephone medical discussion with physician, 5-10 minutes

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Carcinoembryonic antigen (cea) protein level

Injection of drug or substance under skin or into muscle

Injection, eflapegrastim-xnst, 0.1 mg

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Psa (prostate specific antigen) measurement, total

Injection, nivolumab, 1 mg

Blood test, thyroid stimulating hormone (tsh)

Injection, ferric derisomaltose, 10 mg

Cyanocobalamin (vitamin b-12) level

Infusion into a vein for hydration, each additional hour

Folic acid level, serum